GSK, RSV and Shingles
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients and potentially bolster GSK’s faltering sales for both vaccines.
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses compared with separate administration of the vaccines.
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older. The British pharma giant said Wednesday a Phase 3 study evaluating RSV vaccine Arexvy co-administered with Shingrix met the primary endpoint,
RSV Can Be a Killer. New Tools Are Identifying the Most At-Risk Kids
RSV infects almost every child before they turn 2, and kills more than 100,000 infants worldwide each year. Machine learning ...
WISH-TV on MSN1d
Health Spotlight | The truth about RSV
It's that time of year again: the dreaded cold and flu season is on the horizon. But lurking in the shadows is a more ...
The American Journal of Managed Care4d
New RSV Vaccine Is Likely Cost-Effective for Older Adults, Study Finds
Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...
WGAL9d
Pulmonologist talks about RSV: Symptoms, who's most at risk, effectiveness of vaccine
A UPMC pulmonologist talks about the symptoms, explains who is most at risk for a severe infection, and tells us how ...
Health Beat: The truth About RSV
Often dismissed as just another common cold, RSV can be deadly, especially for infants and older people. Hannah and her twin ...
Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line
Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...
Medscape8d
For Which Adults Are RSV Vaccination Programs Cost-Effective?
Medical risk-based approaches outperformed age-based strategies, even when vaccine prices were low, the study authors said.
COVID-19, flu and RSV shots: Do I really need all three?
All flu vaccines for the 2024-25 season will be trivalent, meaning they protect against three different strains of influenza: ...
After years of advocacy by a pediatrician, all Nunavut babies to get RSV immunization
The Nunavut government says it will provide immunization against respiratory syncytial virus to all infants in the territory ...